1. A. Protocol:

   1. (1) Prescriptive authority for hormonal contraception drug therapy shall be exercised solely in accordance with the written protocol for hormonal contraception drug therapy approved by the board.
   2. (2) Any pharmacist exercising prescriptive authority for hormonal contraception drug therapy must maintain a current copy of the written protocol for hormonal contraception drug therapy approved by the board.

2. B. Education and training:

   1. (1) The pharmacist must successfully complete a course of training, accredited by the accreditation council for pharmacy education (ACPE), in the subject of hormonal contraception drug therapy provided by:

      1. (a) the New Mexico pharmacists association or;
      2. (b) a similar health authority or professional body approved by the board.

   2. (2) Training must include study materials and instruction in the following content areas:

      1. (a) mechanisms of action, contraindication, drug interaction and monitoring of hormonal contraception drug therapy;
      2. (b) current standards for prescribing hormonal contraception drug therapy;
      3. (c) identifying indications for use of hormonal contraception drug therapy;
      4. (d) interviewing patient to establish need for hormonal contraception drug therapy;
      5. (e) counseling patient regarding the safety, efficacy and potential adverse effects of drug products for hormonal contraception;
      6. (f) evaluating patient’s medical profile for drug interaction;
      7. (g) referring patient follow-up care with primary healthcare provider;
      8. (h) informed consent;
      9. (i) management of adverse events, including identification, appropriate response, documentation and reporting.
   3. (3) Continuing education: any pharmacist exercising prescriptive authority for hormonal contraception drug therapy shall complete a minimum of 0.1 CEU of live ACPE approved hormonal contraception drug therapy related continuing education every two years.

3. C. Authorized drugs:

   1. (1) Prescriptive authority shall be limited to hormonal contraception drug therapy and shall exclude any device intended to prevent pregnancy after intercourse.
   2. (2) Prescriptive authority for hormonal contraception drug therapy shall be limited to those drugs delineated in the written protocol for hormonal contraception drug therapy approved by the board.

4. D. Records:

   1. (1) The prescribing pharmacist must generate a written or electronic prescription for any dangerous drug authorized.
   2. (2) Informed consent must be documented in accordance with the approved protocol for hormonal contraception drug therapy and a record of such consent maintained in the pharmacy for a period of at least three years.
5. E. Notification: Upon signed consent of the patient or guardian, the pharmacist shall notify the patient’s designated physician or primary care provider of hormonal contraception drug therapy prescribed.

[16.19.26.14 NMAC - N, 6/9/2017; Rn, 16.19.26.13 NMAC, 5/25/2021; A, 2/10/2026]